Literature DB >> 23435596

Lymphedema: experience of a cohort of women with breast cancer followed for 4 years after diagnosis in Victoria, Australia.

Robin J Bell1, Penelope J Robinson, Raychel Barallon, Pamela Fradkin, Max Schwarz, Susan R Davis.   

Abstract

PURPOSE: The aim of this work was to study the incidence and prevalence of self-reported lymphedema in breast cancer survivors between 2 and 4 years following diagnosis, the factors associated with the development of lymphedema and the impact of lymphedema on psychological well-being.
METHODS: We assessed self-reported lymphedema in the BUPA Health Foundation Health and Wellbeing After Breast Cancer Study, a questionnaire-based study of 1,683 women newly diagnosed with their first episode of invasive breast cancer in Victoria, Australia. Psychological well-being was assessed using the Psychological General Well-being Index.
RESULTS: Two years after diagnosis, nearly 20 % of women reported lymphedema and this proportion remained above 18 % 2 years later. However, self-reported lymphedema was a dynamic phenomenon, with the condition resolving in some women and others reporting onset for the first time up to 4 years from diagnosis. Lymphedema 2 years from diagnosis was positively associated with the number of nodes removed at initial surgery, although this variable only explained a small proportion of the likelihood of reporting lymphedema. The presence of lymphedema was associated with lower psychological general well-being.
CONCLUSIONS: Lymphedema after breast cancer treatment frequently has a dynamic pattern and may emerge as an issue for women several years after their initial treatment. It is associated with a lower level of general well-being.

Entities:  

Mesh:

Year:  2013        PMID: 23435596     DOI: 10.1007/s00520-013-1763-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  22 in total

1.  Prevalence of lymphoedema more than five years after breast cancer treatment.

Authors:  T R Lopez Penha; J J G Slangen; E M Heuts; A C Voogd; M F Von Meyenfeldt
Journal:  Eur J Surg Oncol       Date:  2011-09-19       Impact factor: 4.424

2.  Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection.

Authors:  Wesley P Francis; Pamella Abghari; Wei Du; Christine Rymal; Moheen Suna; Mary A Kosir
Journal:  Am J Surg       Date:  2006-11       Impact factor: 2.565

3.  A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population.

Authors:  Jane M Armer; Bob R Stewart
Journal:  Lymphat Res Biol       Date:  2005       Impact factor: 2.589

4.  Endogenous androgen levels and well-being: differences between premenopausal and postmenopausal women.

Authors:  Robin J Bell; Susan Donath; Sonia L Davison; Susan R Davis
Journal:  Menopause       Date:  2006 Jan-Feb       Impact factor: 2.953

5.  Vaccines and risk of lymphoedema--a case report of a breast cancer patient.

Authors:  Teresa Sze Mun Lee; Karl W Baumgart
Journal:  Aust Fam Physician       Date:  2012-06

Review 6.  Lymphedema: classification, diagnosis and therapy.

Authors:  A Szuba; S G Rockson
Journal:  Vasc Med       Date:  1998       Impact factor: 3.239

7.  Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Authors:  Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

8.  Psychological well-being in a cohort of women with invasive breast cancer nearly 2 years after diagnosis.

Authors:  Robin J Bell; Marijana Lijovic; Maria La China; Max Schwarz; Pamela Fradkin; Jo Bradbury; Susan R Davis
Journal:  Support Care Cancer       Date:  2009-08-26       Impact factor: 3.603

Review 9.  Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma.

Authors:  S D Passik; M V McDonald
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

10.  Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.

Authors:  Lee Gravatt Wilke; Linda M McCall; Katherine E Posther; Pat W Whitworth; Douglas S Reintgen; A Marilyn Leitch; Sheryl G A Gabram; Anthony Lucci; Charles E Cox; Kelly K Hunt; James E Herndon; Armando E Giuliano
Journal:  Ann Surg Oncol       Date:  2006-03-02       Impact factor: 5.344

View more
  5 in total

Review 1.  Psychosocial Issues Associated with Breast Cancer-Related Lymphedema: a Literature Review.

Authors:  L H Eaton; N Narkthong; J M Hulett
Journal:  Curr Breast Cancer Rep       Date:  2020-08-25

2.  Breast cancer-related lymphedema after axillary lymph node dissection: does early postoperative prediction model work?

Authors:  Atilla Soran; Ebru Menekse; Mark Girgis; Lori DeGore; Ronald Johnson
Journal:  Support Care Cancer       Date:  2015-09-09       Impact factor: 3.603

3.  Persistent breast pain 5 years after treatment of invasive breast cancer is largely unexplained by factors associated with treatment.

Authors:  Robin J Bell; Penelope J Robinson; Fathima Nazeem; Mary Panjari; Pamela Fradkin; Max Schwarz; Susan R Davis
Journal:  J Cancer Surviv       Date:  2013-08-23       Impact factor: 4.442

4.  Computed Tomography as an Objective Measurement Tool for Secondary Lymphedema Treated With Extracorporeal Shock Wave Therapy.

Authors:  So-Yeon Kim; Hasuk Bae; Hye Min Ji
Journal:  Ann Rehabil Med       Date:  2015-06-30

5.  Integrating Symptoms Into the Diagnostic Criteria for Breast Cancer-Related Lymphedema: Applying Results From a Prospective Surveillance Program.

Authors:  Cheryl L Brunelle; Sacha A Roberts; Nora K Horick; Tessa C Gillespie; Jamie M Jacobs; Kayla M Daniell; George E Naoum; Alphonse G Taghian
Journal:  Phys Ther       Date:  2020-12-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.